about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

BeiGene takes a hit af­ter his­toric $903M Hong Kong IPO with neg­a­tive biotech sen­ti­ment

7 years ago
Financing
China

First-in-hu­man stud­ies in sight, SQZ's cell ther­a­py tech wins over a di­verse group of in­vestors in $72M round

7 years ago
R&D
Discovery

Min­ing re­al world da­ta for drug de­vel­op­ment in­sights, Wood­ford-backed AI firm seeks $77M Lon­don IPO

7 years ago
Financing

Boehringer or­ga­nizes a coali­tion in search of first CF gene ther­a­py, work­ing with re­search, man­u­fac­tur­ing part­ners

7 years ago
R&D
Pharma

Cell Med­ica scoops Kite Phar­ma's Chris Now­ers as CEO; Shire vet jumps to Edi­Gene as CEO

7 years ago
Peer Review

Lil­ly Asian Ven­tures backs Im­pact's PARP re­search again, chip­ping in for $30M Se­ries C led by Decheng Cap­i­tal

7 years ago
Financing
China

No­var­tis on­col­o­gy vet Ste­fan Scher­er joins biotech mi­gra­tion to head clin­i­cal work, CAR-T part­ner­ship at Cel­lec­tis

7 years ago
People

Bris­tol-My­ers, Scripps re­search team touts a new way to con­trol 3D ar­chi­tec­ture of ge­net­ic drugs

7 years ago
Discovery

With high ex­pec­ta­tions on Provenge, Den­dreon is 'sol­d' (again) in $832M deal

7 years ago
Deals

BeiGene bags a stag­ger­ing $903M IPO on the HKEX — and still man­ages to spark some ner­vous fret­ting

7 years ago
Financing
China

As­cle­tis breaks in­to HKEX, briefly ris­ing on hot­ly an­tic­i­pat­ed pub­lic de­but of first biotech

7 years ago
Financing
China

Fresh out of 6 Di­men­sion­s' in­cu­ba­tor, Curon launch­es with $150M and back­ing from Boyu, Temasek

7 years ago
Financing
China

Si­en­na con­cedes fail­ure in piv­otal ac­ne tri­al — will the laser-man­aged ther­a­py work in hair re­duc­tion?

7 years ago
R&D

Af­ter huge mega-round, CStone poach­es Gold­man's Richard Yeh as CFO; Both Hoop­er and Harp­er ex­it Am­gen's re­volv­ing ...

7 years ago
Peer Review

In for the Chi­na biotech gold rush, BeiGene eyes mon­ster $800M-plus Hong Kong IPO

7 years ago
Financing
China

As­cle­tis reaps record $400M from Hong Kong in­vestors in the ex­change's first-ever pre-rev­enue biotech list­ing

7 years ago
Financing
China

Pfiz­er plans $465M man­u­fac­tur­ing fa­cil­i­ty at Michi­gan base; Chi­na's Ts­inghua Uni­ver­si­ty inks dis­cov­ery deal with ...

7 years ago
News Briefing

Mer­ck claims a need­ed win for Keytru­da with in­ter­im OS da­ta in head and neck can­cer

7 years ago
R&D

API man­u­fac­tur­er Cam­brex buys Ha­lo Phar­ma for $425M — ven­tur­ing in­to fin­ished dose man­u­fac­tur­ing

7 years ago
Deals

GSK gains a PRV along­side FDA ap­proval for re­cur­ring malar­ia treat­ment

7 years ago
Pharma

Sang­amo puts down $84M to ac­quire Tx­Cell, div­ing in­to CAR-Treg space, au­toim­mune dis­eases

7 years ago
Deals

An­tho­ny Quinn ce­ments Ae­glea CEO spot; Hu­man Longevi­ty bumps David Karow up to the top

7 years ago
Peer Review

PureTech grabs up to $36M from Roche to re­search milk-in­spired de­liv­ery plat­form

7 years ago
Pharma

Aridis Phar­ma seeks $35M to fight in­fec­tions with im­munother­a­pies — lat­est in an IPO streak

7 years ago
Financing
First page Previous page 113114115116117118119 Next page Last page
A service from the Financial Times